Study on the influential factors of blood concentration for duloxetine based on therapeutic drug monitoring
- VernacularTitle:基于治疗药物监测的度洛西汀血药浓度影响因素研究
- Author:
Yang LUN
1
;
Liguang DUAN
2
;
Feiyue AN
2
;
Ran FU
1
,
3
;
Jing YU
1
,
3
;
Chaoli CHEN
1
;
Mengqiang ZHAO
1
,
3
;
Shi SU
1
,
3
;
Yang SONG
1
,
3
;
Jiaqi WANG
1
;
Yuhang YAN
1
;
Chunhua ZHOU
1
Author Information
1. Dept. of Clinical Pharmacy，the First Hospital of Hebei Medical University，Shijiazhuang 050023，China
2. Dept. of Pharmacy，the First Hospital of Hebei Medical University，Shijiazhuang 050023，China
3. Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province，Shijiazhuang 050031，China
- Publication Type:Journal Article
- Keywords:
duloxetine;
genotype;
therapeutic drug monitoring;
depressive disorders;
individualized medication
- From:
China Pharmacy
2025;36(6):727-731
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the main factors influencing the blood concentration of duloxetine， and provide a scientific basis for the individualized use of duloxetine. METHODS Retrospective analysis was conducted on 434 inpatients with depressive disorders at the First Hospital of Hebei Medical University， who were treated with duloxetine and underwent blood concentration monitoring between January 2022 and April 2024. The study examined the impact of various factors， including gender， age， body mass index （BMI）， gene phenotypes， combined medication， drug type （original/generic）， and genotyping results of gene single nucleotide polymorphism loci， on blood concentration and the concentration-to-dose （C/D） after dose adjustment. RESULTS The blood concentration of duloxetine was 76.65 （45.57， 130.31） ng/mL， and C/D was 0.96 （0.63， 1.60） ng·d/（mL·mg）. The blood concentration of duloxetine was positively correlated with the daily dose of administration （R2＝0.253 7， P＜0.001）. Blood concentration of duloxetine in 38.94% of patients exceeded the recommended range specified in the guidelines. Gender， age， BMI， combined use of CYP2D6 enzyme inhibitors， and CYP2D6 and CYP1A2 phenotypes had significant effects on C/D of duloxetine （P＜0.05）. CONCLUSIONS The patient’s age， gender， BMI， combined medication， and genetic phenotypes are closely related to the blood concentration of duloxetine.
